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ABSTRACT 
Background & Aims: In the last decade pegylated interferon-α (Peg-INF-α) plus 
ribavirin (RBV) was the standard treatment of chronic hepatitis C for genotype 1, and 
it remains the standard for genotypes 2 and 3. Recent studies reported associations 
between RBV-induced anemia and genetic polymorphisms of concentrative 
nucleoside transporters such as CNT3 (encoded by SLC28A3) and inosine 
triphosphatase (encoded by ITPA). We aimed to study genetic determinants of RBV 
kinetics, efficacy and treatment associated anemia. 
Methods: We included 216 patients from two Swiss study cohorts (61% HCV 
genotype 1, 39% genotypes 2 or 3). Patients were analyzed for SLC28A2 single 
nucleotide polymorphism (SNP) rs11854484, SLC28A3 rs56350726 and SLC28A3 
rs10868138 as well as ITPA SNPs rs1127354 and rs7270101 and followed regarding 
treatment-associated hemoglobin changes and sustained virological response (SVR). 
In 67 patients RBV serum levels were additionally measured during treatment. 
Results: Patients with SLC28A2 rs11854484 genotype TT had higher dosage- and 
body weight-adjusted RBV levels than those with genotypes TC or CC (p=0.02 and 
p=0.06 at weeks 4 and 8, respectively). ITPA SNP rs1127354 was associated with 
hemoglobin drop ≥ 3 g/dl during treatment in genotype (relative risk (RR)=2.1, 95%CI 
1.3-3.5) as well as in allelic analyses (RR=2.0, 95%CI 1.2-3.4). SLC28A3 
rs56350726 was associated with SVR in genotype (RR=2.2; 95% CI 1.1-4.3) as well 
as in allelic analyses (RR=2.0, 95% CI 1.1-3.4). 
Conclusions: The newly identified association between RBV serum levels and 
SLC28A2 rs11854484 genotype as well as the replicated association of ITPA and 
SLC28A3 genetic polymorphisms with RBV induced anemia and treatment response 
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may support individualized treatment of chronic hepatitis C and warrant further 
investigation in larger studies. 
 
Key words: Ribavirin, chronic hepatitis C, ITPA, SLC28 transporters, anemia, 
therapy response 
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Introduction 
Worldwide, 130-200 million people are infected with the hepatitis C virus (HCV) and 
350,000 people die from HCV related end-stage liver disease each year[1]. For the 
last decade, standard treatment for chronic hepatitis C has been combination therapy 
with pegylated interferon-α (Peg-INF-α) and ribavirin (RBV)[2]. Although its 
mechanism of action remains incompletely understood, RBV is important for 
achieving early virological response (EVR), sustained virological response (SVR) 
and, in particular, the reduction of relapses[3-5]. 
In general, RBV is well tolerated, but it frequently induces dose-dependent anemia, 
requiring dose modifications in up to 22% of patients[5-6]. Current recommendations 
call for RBV dose reduction if hemoglobin (Hb) levels drop below 10 g/dl and demand 
treatment discontinuation at a Hb level < 8.5 g/dl, or suggest adjuvant treatment with 
erythropoietic growth factors[7]. However, RBV dose reduction can adversely affect 
its efficacy[8]. In turn, in a study of 118 untreated HCV genotype (GT) 1 infected 
patients, a significant Hb decline during antiviral treatment was associated with a 
higher SVR rate, while a lack of Hb decline correlated with decreased SVR[9]. These 
data suggest that the extent of Hb decline could be a pharmacodynamic marker of 
RBV exposure, which may predict its antiviral effect more precisely than the RBV 
dose. 
Several genetic polymorphisms have recently been found to influence RBV induced 
anemia. A genome-wide association study identified two single nucleotide 
polymorphisms (SNPs) (rs1127354, rs7270101) in the gene coding for inosine 
triphosphatase (ITPA), which were associated with RBV related anemia[10]. 
Interestingly, rs1127354 and rs7270101 were shown to markedly reduce ITPA 
activity[11], which causes a higher concentration of inosine triphosphate (ITP) in 
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erythrocytes[12]. Higher ITP concentrations are believed to protect against RBV 
induced ATP depletion and consequently anemia[13-14] by substituting for 
erythrocyte GTP in the biosynthesis of ATP[15]. Interestingly, in the above-mentioned 
study there was no association between these polymorphisms and treatment 
response, which would be expected based on such a mechanism. 
Another host determinant of interest is the family of concentrative nucleoside 
transporters (CNTs), encoded by SLC28 genes. CNTs mediate sodium-dependent 
uptake of nucleosides and their analogues including RBV. CNT2 (encoded by 
SLC28A2) is a purine-preferring transporter, whereas CNT3 (encoded by SLC28A3) 
has a more global spectrum for purines and pyrimidines[16]. In the human 
duodenum, mRNA expression of SLC28A2 is 15-fold higher compared to other 
uptake transporters[17] and it is also expressed in the kidney as well as other parts of 
the gut. CNT2 (encoded by SLC28A2) is the main uptake transporter for RBV in the 
small intestine, mainly the jejunum[18]. In line with its prominent role in RBV uptake, 
SNP rs11854484 in the coding region was the best independent predictor for SVR in 
115 HCV-infected patients in the study by D’Avolio et al.[19]. 
CNT3 (SLC28A3) is considered to be another important target in RBV uptake and 
metabolism. Transcripts of SLC28A3 are found in the pancreas, the duodenum, the 
liver and other organs[20]. Recently, genetic polymorphisms 
rs10868138G/rs56350726T have been reported as being protective against RBV 
induced anemia in a population of 169 patients infected with HCV genotype 1, but no 
association with therapeutic outcomes was found[21]. 
Replication of genome-wide association studies by a targeted approach in different 
populations is an important contribution to their validation. In addition, previous 
studies did not simultaneously evaluate the effects and possible interactions between 
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genetic polymorphisms of SLC28 and ITPA. Therefore, the present study aimed to 
examine the isolated and combined contribution of SLC28 and ITPA variants on RBV 
plasma concentrations, RBV induced anemia and treatment outcome. 
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Materials and Methods 
 
Study design and patients 
We included 216 patients in the main analyses. Among those 194 patients were from 
the Swiss Hepatitis C Cohort Study (SCCS)[22] (110 GT 1, 84 GT 2 or GT 3), and 
another 22 patients from Swiss Association for the Study of the Liver (SASL) study 
24 (GT 1). Detailed criteria for selection in both cohorts are presented in Figure 1. In 
addition, we studied another 13 patients undergoing antiviral therapy with Peg-
INF/RBV plus the more recently introduced direct acting antivirals (DAA) Telaprevir 
or Boceprevir. However, in order to maintain homogeneity of our study population, 
these were not included in the main analyses. The study protocol was approved by 
the responsible ethics committees of all participating centres and informed consent 
for genetic analyses was obtained from each patient. Baseline patient characteristics 
are reported in Table 1. All patients received standard treatment with Peg-INF-α and 
RBV for 24 or 48 weeks according to HCV genotype. Inclusion criteria were age >18 
years as well as positive anti-HCV antibody test and HCV RNA. Patients with HBV or 
HIV coinfections (positive HBsAg or anti-HIV antibody), alcohol consumption >40 
g/day (assessment by questionnaire) and morbid obesity (BMI >40 kg/m²) were 
excluded. As outlined in Figure 1 sustained therapeutic response 6 months after end 
of treatment was available in 197/216 patients due to loss of follow-up. Hb levels 
between weeks 4 and 12 were reported in 170/216 patients and used to assess the 
minimal Hb level. In a subgroup of 67 patients (45 from the SCCS and 22 from 
SASL-24) with available genomic DNA, RBV levels were measured at therapy weeks 
4 and 8. RBV levels were adjusted to drug dosage per body weight (mg/kg). Patients 
received either standard body weight-based dosages (800-1200 mg; n=36) or doses 
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adjusted according to target drug levels > 3.7 µg/mL (1400-3200 mg; n=13). Since 
RBV dosage was adjusted during the course of treatment only drug levels at weeks 4 
and 8 were used for our analysis. RBV drug levels were determined by high-
performance liquid chromatography mass spectrometry (HPLC/MS) (Thermo 
Finnigan TSQ 7000, Thermo Fisher Scientific, Reinach, Switzerland).  
 
DNA isolation and genotyping 
DNA was isolated from peripheral blood mononuclear cells (PBMCs) by using the 
QIAmp DNA MiniKit (Qiagen, Valencia, CA). After measurement of DNA 
concentrations, genotyping for ITPA SNPs rs1127354 (C>A) and rs7270101 (A>C) 
was performed by using TaqMan SNP genotype assays C_27465000_10/ 
C_29168507_10 (Applied Biosystems, Carlsbad, CA). For the transporters SLC28A2 
and SLC28A3, the following Taqman SNP genotype assays were used: rs11854484 
(C>T) C_3079502_10, rs56350726 (A>T) C_25954718_20 and rs10868138 (C>T) 
C_25954882_20 (Applied Biosystems, Carlsbad, CA). Combined analysis of ITPA 
function was performed and classified according to the criteria published by Fellay et 
al.[10], i.e. wildtype (100% ITPA activity), + (rs7270101 heterozygosity, 60% IPTA 
activity), ++ (rs1127354 heterozygosity and rs727101 homozygosity, 30% ITPA 
activity) and +++ (combined heterozygosity or rs1127354 homozygosity, very low 
residual ITPA activity. 
 
Statistical analyses 
Statistical analyses and graphs were done with SPSS (19.0, SPSS Inc., Chicago, IL) 
and STATA (12.1 for MacOS X, StataCorp, College Station, TX). The observed 
distribution of homozygous and heterozygous patients was compared to the 
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expected distribution according to the NCBI SNP database. Differences in 
therapeutic response (SVR vs. non-SVR including non-responder, partial responder 
and relapser) and Hb drop > 3 g/dl were calculated as relative risks with Fisher’s 
exact test-based 95% confidence intervals. RBV serum levels at weeks 4 and 8 were 
compared using the non-parametric Wilcoxon-Mann-Whitney-test, where p-values ≤ 
0.05 were considered as statistically significant. In order to explore potential effects 
of liver disease stage, we also performed analyses with stratification over the 
presence of cirrhosis. These allowed us to evaluate relative risk estimates restricted 
to either non-cirrhotic or cirrhotic patients, as well as combined Mantel-Haenszel 
pooled estimates with robust control for possible confounding by liver cirrhosis. 
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Results 
Allelic and genotype frequencies 
Allelic and genotype frequencies of analyzed genetic variants for ITPA, SLC28A2 
and SLC28A3 are listed in Table 2. Allelic and genotype frequencies were 
comparable to those reported in the NCBI SNP database 
(www.ncbi.nlm.nih.gov/SNP/) except for rs11854484, where the C allele occurred 
more frequently in our cohort. 
 
RBV concentrations and SLC28 genotypes 
Figure 2 shows RBV concentrations of the three studied SLC28 uptake transporter 
polymorphisms in the 67 patients with available steady state RBV levels at weeks 4 
and 8. Patients carrying the TT genotype of SLC28A2 rs11854484 (Figure 2 A) had 
higher RBV levels at weeks 4 and 8 than those with TC or CC genotype (mean ± SD 
0.19±0.06 mg/l vs. 0.15±0.06 mg/l at week 4, p=0.02; and 0.21±0.09 mg/l vs. 
0.17±0.06 mg/l at week 8; p=0.06). Part of our study population is from the SASL 
study 24, where different RBV dosages were used to obtain certain target RBV levels 
during treatment. The observation of higher RBV levels in TT genotype (SLC28A2 
rs11854484) was also found in the subgroup of SASL-24 patients that were targeted 
to RBV drug levels > 3.7 µg/mL and therefore received higher RBV dosages. In 
contrast, no significant differences were observed for TT vs. CT_CC genotypes of 
rs56350726 and rs10868138 (Figure 2 B and C). No difference in RBV serum levels 
was observed in cirrhotic vs. non-cirrhotic patients. 
Furthermore 13 patients undergoing antiviral therapy with Peg-INF/RBV and 
Telaprevir or Boceprevir and available RBV serum levels during therapy weeks 4 and 
8 met the inclusion criteria. In this small subcohort we also found higher RBV 
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concentrations in patients with TT genotype of SLC28A2 rs11854484 than those with 
TC or CC genotype (0.16±0.08 mg/l vs. 0.12±0.08 mg/l at week 4; and 0.26±0.13 
mg/l vs. 0.19±0.07 mg/l at week 8), but as expected with regard to the small number 
of patients these differences were statistically not significant. 
 
RBV induced anemia and SLC28A2 and ITPA genotypes  
In 101 of 170 patients (59.4%) Hb levels dropped > 3 g/dl during antiviral treatment. 
Associations of SLC28 and ITPA polymorphisms with Hb drop > 3 g/dL during 
antiviral therapy are presented in Table 3 and Figure 3. 
For SLC28 transporter genetic variants we observed no significant differences. In 
contrast, homozygous carriers of the ITPA rs1127354 CC genotype had a 2.1 times 
significantly higher risk for Hb drop > 3 g/dL than patients with CA genotype, and also 
the allelic analyses indicated a 2 times significantly elevated risk for the C allele.  
In addition Figure 4 presents percentages of patients with pronounced Hb drop over 
strata of different ITPA activities based on their genotype (ITPA rs1127354 and 
rs7270101 combinations according to Fellay’s ITPA activity class). As shown, the 
more pronounced the ITPA deficiency, the lower the risk of RBV induced anemia.  
 
SVR and SLC28 and ITPA genotypes 
Associations of therapeutic outcome with SLC28A and ITPA genetic variants are 
presented in Table 4 and Figure 3. Carriers of the homozygous SLC28A3 
rs56350726 TT genotype had a significantly 2.2 times higher risk for reaching SVR 
compared to AT and AA carriers. Allelic analysis revealed a similar result with a 2 
times higher chance for SVR associated with the T allele. An association with a 
  
 13
relative risk of 1.5 and 1.4 with borderline statistical significance was detected for 
SLC28A3 rs10868138 in genotypic and allelic analyses, respectively. 
In contrast, no correlation of SVR with ITPA, neither in genotype or allelic analysis 
nor with its functional Fellay class could be observed. 
Furthermore, the combined analysis of overall ITPA activity according to Fellay and 
SLC28A variants together revealed no significant additive effects on either treatment 
related anemia or SVR (data not shown). 
 
Genetic associations stratified over the presence of cirrhosis 
Because cirrhotic patients are a difficult to treat population for reaching therapy 
response in antiviral therapy and the effects of genetic factors may differ in this 
subpopulation we conducted additional stratified analyses for all associations 
reported above. However, effect estimates were closely similar when analyses were 
restricted to patients without cirrhosis (relative risk of homozygous SLC28A3 
rs56350726 TT genotype for reaching SVR; RR 2.7, 95% CI 1.1-6.5), or calculated 
as pooled estimates from strata with and without cirrhosis according to Mantel-
Haenszel, where also tests for heterogeneity did not indicate statistically significant 
differences between those two strata. 
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Discussion  
Although the precise mechanism of action is still unknown, providing HCV-infected 
patients with adequate doses of RBV during antiviral treatment is pivotal for 
achieving an optimal therapeutic response. Thus, the extent of RBV exposure is an 
important determinant of SVR. However, data on possible associations between RBV 
levels and polymorphisms of genes determining RBV pharmacokinetics is scarce. 
Pharmacokinetic studies have recently shown that higher RBV levels during 
treatment are associated with a higher probability of early, rapid and sustained 
virological response[23-24]. RBV pharmacokinetics are complex, with high inter- and 
intrapatient variability[25] and a long terminal elimination half-life. As SLC28A 
transporters are mainly involved in RBV uptake into cells, they are of particular 
interest for genetic analysis. 
 
The present study links SLC28A2 rs11854484 polymorphism to higher RBV drug 
levels during combined Peg-INF-α/RBV treatment, and SLC28A3 rs56350726 variant 
was associated with SVR in this study. No additive effects of ITPA variants and 
combined activity could be observed. 
 
To characterize the modulating effect of SLC28 transporter variants on RBV levels 
during antiviral therapy their associations with RBV drug levels in vivo and treatment 
related outcome parameters were analyzed. SLC28A2 is the main uptake transporter 
in the small intestine[18]. Uptake kinetics for different genetic polymorphisms were 
analyzed in a recent study in Xenopus laevis oocytes[16] but no difference in uptake 
of RBV in the analyzed genetic variants could be detected in this experimental 
setting. In contrast to these in vitro uptake kinetics, the presence of homozygote 
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alleles TT in our patient population was significantly associated with higher serum 
RBV levels at both weeks 4 and 8. Despite these discrepant findings, we conclude 
from our data that the TT genotype might facilitate RBV absorption in the small 
intestine, which in turn may lead to increased RBV bioavailability. In support of an 
increased RBV bioavailability we found also a trend towards increased frequency of 
treatment related anemia for the same allelic variant in our study population. Finally, 
a functional consequence of the respective SLC28A2 rs11854484 variant in vivo is 
also supported by a study from D’Avolio et al. reporting a significant association of 
SLC28A2 rs11854484 with SVR[19]. 
Concerning other common genetic uptake transporter variants and their potential 
impact on RBV induced adverse effects a recent study showed an association 
between SLC28A3 rs10838138 genotype and SLC28A3 rs56350726/rs10838138 
haplotype to RBV induced anemia in 169 HCV patients[21]. Accordingly, the same 
genetic variants have also been analyzed in the present study population without 
significant association to a treatment induced Hb decline of > 3 g/dL. However, in our 
study patients with the TT genotype had a significant higher relative chance for 
reaching SVR than patients with SLC28A3 rs56350726 variant who were protected 
against anemia[21]. These findings also suggest a functional involvement of 
SLC28A3 variants, possibly due to an effect on RBV uptake. However, in our 
subgroup of 49 patients with available RBV levels during treatment we did not 
observe a significant difference in RBV levels for either rs56350726 or rs10838138. 
The power of this subgroup analysis is limited and therefore does not preclude such 
a functional impact of SLC28A3 variants on RBV uptake. 
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Recent studies have reproducibly identified polymorphic variation of the ITPA gene 
leading to enzymatic ITPA deficiency as a major determinant of RBV induced 
hemolytic anemia[26-29]. ITPA deficiency results from two SNPs rs1127354 
(missense variant in exon 2) and rs7270101 (splicing-altering SNP located in the 
second intron) of which both minor alleles cause reduced or non-detectable ITPA 
activity. Patients who are heterozygous for rs1127354 and rs7270101 have a lower 
risk for Hb drop > 3 g/dl during antiviral therapy[10]. This association was confirmed 
in our study for allelic and genotypic rs1127354 variants. And similarly to the study by 
Fellay et al., no association between ITPA polymorphisms and therapy outcome was 
found. To date ITPA polymorphisms have only been associated to therapy response 
in selected subgroups of larger study populations[30-31]. Given the demonstrated 
functional effects on RBV metabolism and uptake at different levels, additive effects 
together with SLC28A transporter variants on both treatment-induced anemia and 
therapy success could be hypothesized. However, no such effects of coinheritance 
were observed in the present study and have not been reported elsewhere to date. 
In addition, our stratified analyses over the presence of cirrhosis were able to exclude 
that this factor may have confounded our results. 
 
Most recently, DAAs (Telaprevir and Boceprevir) were registered in the U.S. and 
Europe for the treatment of patients with HCV GT 1 infection. The decreased viral 
clearance rates in the RBV free treatment arms of recent clinical studies [32-33] 
show the importance of RBV as a backbone in combination therapy with DAAs at 
least in the near future, and treatment-related anemia will remain a clinical challenge. 
In our patient database we also identified 13 eligible patients with antiviral triple 
therapy treatment. Due to the small patient number separate analyses of this 
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additional population of interest suffered from a lack of statistical power. However 
results for RBV concentrations and effect estimates for genetic associations did not 
suggest major differences, and future studies may further investigate this population 
with current standard of care. 
 
For interpretation of our data, it is important to note that the majority of patients were 
recruited from the SCCS in a retrospective fashion. Together with the patients from 
SASL study 24, the study design allows the recruitment of a considerable number of 
patients with available RBV levels during treatment simultaneously fulfilling all in- and 
exclusion criteria (Figure 1). Nevertheless, the power of the RBV level subcohort is 
still marginal and requires the inclusion of different HCV genotypes.  
 
The present study contributes to the understanding of genetic variants involved in 
RBV bioavailability as it shows an association of increased RBV levels and hemolytic 
anemia with SLC28A2 rs11854484 TT genotype. Further associations between SVR 
and SLC28A3 rs56350726 in this study are well in accordance with increased 
hemolytic anemia observed in other cohorts. In summary, these data place SLC28A 
transporter variants in a central position in complex RBV pharmacokinetics. Further 
understanding of the genetic determinants underlying RBV pharmacokinetics should 
contribute to optimize an individualized treatment that can be envisaged in the near 
future. 
  
 18
References 
[1] Gravitz L. Introduction: a smouldering public-health crisis. Nature 2011;474:S2-4. 
[2] Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J 
Med 2006;355:2444-2451. 
[3] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. 
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 
2002;347:975-982. 
[4] Kubota R, Komiyama T, Kumagai N, Kimijima M, Mitsuki K, Uetake J, et al. Optimal 
erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological 
response in patients with chronic hepatitis C caused by genotype 1b infection. Hepat Res 
Treat 2010;2010:495928. 
[5] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et 
al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for 
initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. 
[6] Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-
induced anemia: mechanisms, risk factors and related targets for future research. Curr Med 
Chem 2006;13:3351-3357. 
[7] McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in 
patients infected with hepatitis C virus. Liver Int 2006;26:389-398. 
[8] Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early 
virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with 
chronic hepatitis C. Hepatology 2003;38:645-652. 
[9] Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al. 
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic 
response rate. Gastroenterology 2010;139:1602-1611, 1611 e1601. 
[10] Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene 
variants protect against anaemia in patients treated for chronic hepatitis C. Nature;464:405-
408. 
[11] von Ahsen N, Oellerich M, Armstrong VW. Characterization of the inosine 
triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and 
promoter function. Ther Drug Monit 2008;30:16-22. 
[12] Fraser JH, Meyers H, Henderson JF, Brox LW, McCoy EE. Individual variation in 
inosine triphosphate accumulation in human erythrocytes. Clin Biochem 1975;8:353-364. 
[13] De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. 
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus 
infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004. 
[14] Grattagliano I, Russmann S, Palmieri VO, Juni P, Bihl F, Portincasa P, et al. Low 
membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in 
hepatitis C. Hepatology 2004;39:1248-1255. 
[15] Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al. 
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by 
adenylosuccinate synthase function. Gastroenterology;140:1314-1321. 
[16] Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M, et al. Genetic 
analysis and functional characterization of polymorphisms in the human concentrative 
nucleoside transporter, CNT2. Pharmacogenet Genomics 2005;15:83-90. 
[17] Shin HC, Landowski CP, Sun D, Vig BS, Kim I, Mittal S, et al. Functional expression 
and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from 
human duodenum. Biochem Biophys Res Commun 2003;307:696-703. 
  
 19
[18] Patil SD, Ngo LY, Glue P, Unadkat JD. Intestinal absorption of ribavirin is 
preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res 
1998;15:950-952. 
[19] A. D'Avolio AC, M. Siccardi, L. Baietto, M. Simiele, S. Patanella, D. Aguilar 
Marucco, G. Cariti, A. Calcagno, M. Sciandra, A. Smedile, F.G. De Rosa, S. Bonora, M. 
Rizzetto, G. Di Perri. SLC28A2 65C>T predict sustained virological response in patients with 
hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 
1/4. .  EASL; 2010; Vienna: Journal of Hepatology; 2010. p. S463. 
[20] Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et al. Molecular 
identification and characterization of novel human and mouse concentrative Na+-nucleoside 
cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine 
nucleosides (system cib). J Biol Chem 2001;276:2914-2927. 
[21] Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Sarrazin C, Berg T, et al. Role of 
nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection 
against anemia in patients with chronic hepatitis C. Pharmacogenet Genomics;21:289-296. 
[22] Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F. Cohort 
Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007;36:731-737. 
[23] Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and 
pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 
2000;22:555-565. 
[24] Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, et al. 
Ribavirin exposure after the first dose is predictive of sustained virological response in 
chronic hepatitis C. Hepatology 2008;47:1453-1461. 
[25] Jain MK, Zoellner C. Role of ribavirin in HCV treatment response: now and in the 
future. Expert Opin Pharmacother 2010;11:673-683. 
[26] Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, et al. 
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or 
outcome after treatment with pegylated interferon and ribavirin. Antivir Ther;16:685-694. 
[27] Nishimura T, Osaki R, Shioya M, Imaeda H, Aomatsu T, Takeuchi T, et al. 
Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced 
anemia in chronic hepatitis C patients. Mol Med Report;5:517-520. 
[28] Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, et al. 
ITPA gene variant protects against anemia induced by pegylated interferon-alpha and 
ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res;40:1063-1071. 
[29] Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, et al. Influence of 
ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, 
ribavirin, and telaprevir. Hepatology;53:415-421. 
[30] Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, et al. 
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or 
outcome after treatment with pegylated interferon and ribavirin. Antivir Ther 2011;16:685-
694. 
[31] Thompson A. J. FJ, Ge D., Urban T., Shianna K., Sulkowski M., Muir A., Afdhal N., 
Jacobson I., Esteban R., Poordad F., Lawitz E., Mc Cone J., Shiffmann M., Galler G., Lee W., 
Reindollar R., King J., Kwo P., Ghalib R., Freilich B., Nyberg L., Patel K., Tillmann H., 
Noviello S., Bopari N., Koury K., Pedicone L., Brass C., Albrecht J.K., Goldstein D., Mc 
Hutchison J.G. Genome wide analysis of patients from the IDEAL study identifies a causal 
role for ITPA gene variation in ribavirin induced hemolytic anemia.  EASL. Vienna: Journal 
of Hepatology; 2010. p. S470. 
[32] S. Zeuzem VS, T. Asselah, JP. Bronowicki, E. Ceausus, A.W. Lohse, A. Streinucercel, 
L. Preotescu, J. Moussalli, B. Muellhaupt, M. Schuchmann, M. Bourliere, F. Calinas, M. Buti, 
  
 20
S.K. Roberts, E.J. Gane, J.O. Stern, G. Nehmiz, H. Bonaventura, W.O. Boecher, F.J. Mensa. 
Virological response too an interferon-free refimen of BI201335 and BI207127, with and 
withourt ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 
12 interim results of the SOUND-C2 study.  AASLD. San Francisco: Hepatology; 2011. p. 
1436A. 
[33] Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, et al. The 
protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with 
ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology;55:749-758. 
 
 
 
 
 
 
 
 
  
 21
TABLES 
 
Table 1: Characteristics of the overall study population 
 
 n % 
   
Total 216 100 
   
Sex   
  Female 76 35.2 
  Male 140 64.8 
   
Genotype   
  1  132 61.1 
  2 or 3 84 38.9 
   
Cirrhosis   
  Yes 35 16.2 
  No 153 70.8 
  Unknown 28 13.0 
   
Sustained virological response   
  Yes 102 47.2 
  No 95 44.0 
  Unknown 19 8.8 
   
Hemoglobin decrease ≥ 3 g/dl during therapy   
  Yes 101 46.8 
  No 69 31.9 
  Unknown 46 21.3 
   
Ribavirin plasma concentrations available   
  Yes 67 31.0 
  No 149 69.0 
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Table 2: Observed and reported allelic frequencies in the study population compared 
to frequencies reported in the NCBI databank 
 
Allele / SNP Proportion (95% CI) of alleles in 
the study population 
(216 patients) 
Proportion reported in NCBI 
reference population 
   
SLC28 genes   
   
  rs11854484   
   T 0.54 (0.49-0.59) 0.64 
   C 0.46 (0.41-0.51) 0.36 
   
  rs56350726   
   T 0.94 (0.91-0.96) 0.92 
   A 0.06 (0.04-0.09) 0.08 
   
  rs10868138   
   T 0.93 (0.90-0.95) 0.90 
   C 0.07 (0.05-0.10) 0.10 
   
   
ITPA genes   
   
  rs1127354   
   C 0.94 (0.92-0.96) 0.92 
   A 0.06 (0.04-0.08) 0.08 
   
  rs7270101   
   A 0.86 (0.83-0.89) 0.87 
   C 0.14 (0.11-0.17) 0.13 
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Table 3: Absolute risks and risk ratios (RR) for Hb decreases ≥ 3 g/dl by genotype in 
170 patients with available Hb measurements 
 
Genotype Variant 1 Risk (%)* Variant 2 Risk (%)* RR (95% CI)** 
      
SLC28       
  rs11854484 CT or CC 57.1 TT 64.7 1.1 (0.9-1.5) 
  rs56350726 AT or AA 55.5 TT 59.9 1.1 (0.7-1.6) 
  rs10868138 TC or CC 56.5 TT 59.9 1.1 (0.7-1.5) 
      
ITPA      
  rs1127354 CA 30.0 CC 63.3 2.1 (1.3-3.5) 
  rs7270101 CA or CC 48.8 AA 63.0 1.3 (0.9-1.8) 
      
Allele Variant 1 Risk (%)* Variant 2 Risk (%)* RR (95% CI)** 
      
SLC28      
  rs11854484 C 55.6 T 62.4 1.1 (0.9-1.3) 
  rs56350726 A 59.1 T 59.4 1.0 (0.7-1.4) 
  rs10868138 C 60.7 T 59.3 1.0 (0.7-1.3) 
      
ITPA      
  rs1127354 A 30.0 C 61.3 2.0 (1.2-3.4) 
  rs7270101 C 49.0 A 61.2 1.2 (1.0-1.6) 
      
 
 
*Absolute risk (%) of Hb decrease ≥ 3 g/dl for patients with respective gene variants 
**Risk ratio with variant 1 as reference (risk variant 2 / risk variant 1) 
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Table 4: Absolute risks and risk ratios (RR) for SVR by genotype in 197 patients with 
known therapeutic response 
 
Genotype Variant 1 Risk (%)* Variant 2 Risk (%)* RR (95% CI)** 
      
SLC28      
  rs11854484 CT or CC 52.5 TT 50.0 1.0 (0.7-1.3) 
  rs56350726 AT or AA 25.0 TT 54.1 2.2 (1.1-4.3) 
  rs10868138 TC or CC 38.1 TT 53.4 1.4 (0.9-2.3) 
      
ITPA      
  rs1127354 CA 60.9 CC 50.6 0.8 (0.6-1.2) 
  rs7270101 CA or CC 56.3 AA 50.3 0.9 (0.7-1.2) 
      
Allele Variant 1 Risk (%)* Variant 2 Risk (%)* RR (95% CI)** 
      
SLC28      
  rs11854484 C 50.8 T 52.3 1.0 (0.9-1.3) 
  rs56350726 A 27.2 T 53.2 2.0 (1.1-3.4) 
  rs10868138 C 34.6 T 53.0 1.5 (1.0-2.4) 
      
ITPA      
  rs1127354 A 60.9 C 51.2 0.8 (0.6-1.2) 
  rs7270101 C 52.6 A 51.6 1.0 (0.7-1.3) 
      
 
*Absolute risk (%) of SVR for patients with respective gene variants 
**Risk ratio with variant 1 as reference (risk variant 2 / risk variant 1) 
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FIGURE LEGENDS 
 
Figure 1: Patient recruitment with inclusion and exclusion criteria. 
 
 
Figure 2: Boxplots for RBV plasma levels (adjusted to RBV dose/body weight) at 
weeks 4 and 8 during antiviral treatment by genetic SLC28A2 and SLC28A3 variants 
in 67 patients. 
 
 
Figure 3: Frequencies of SLC28 and ITPA genotypes, stratified over categories of 
Hb drop (N=170) and SVR (N=197) 
 
 
Figure 4: Association between ITPA deficiency and proportion of patients with Hb 
decreases ≥ 3 g/dl. 
+++ = low residual ITPA activity with combined heterozygosity or rs1127354 
homozygosity ++ = 30% ITPA activity with rs1127354 heterozygosity or rs7270101 
homozygosity 
+ = 60% ITPA activity with rs7270101 heterozygosity 
none = wildtype ITPA activity. 
 
  
 
 
Swiss Hepatitis C Cohort Study 
(SCCS) 
Adult patients (>18 years) and HCV antibody 
positive by immunoblot 
 
Exclusion criteria:  
coinfection with HBV or HIV, alcohol  
> 40g/day and morbid obesity (BMI>40) 
Swiss Association for the Study of 
Liver Diseases Study (SASL-24) 
Adult patients (18-65 years) and HCV antibody 
positive by immunoblot, GT 1 
 
Exclusion criteria:  
coinfection with HBV or HIV, alcohol  
> 40g/day, prior RBV treatment 
 
Inclusion criteria: combined therapy with Peg-IFN-α and RBV, 
available blood samples and genetic consent 
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